The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 78-87

  Sallee, Floyd R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenergic agonist; Attention deficit hyperactivity disorder; Clonidine; Guanfacine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; CLONIDINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GUANFACINE; METHYLPHENIDATE; NORADRENALIN; PLACEBO; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; PSYCHOSTIMULANT AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT;

ADD ON THERAPY; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED RELEASE FORMULATION; DEHYDRATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; IRRITABILITY; LETHARGY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PROTEIN SYNTHESIS INHIBITION; PULSE PRESSURE; QRS COMPLEX; QT INTERVAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; SYNCOPE; UPPER ABDOMINAL PAIN; XEROSTOMIA; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; ELECTROCARDIOGRAPHY;

ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; CLONIDINE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; GUANFACINE; HUMANS; METHYLPHENIDATE;

EID: 78049499521     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2204     Document Type: Review

References (72)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2008. Vital Health Stat 10. 2009;244:1-81.
3. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28(4):265-273.
4. Cuffe SP, Moore CG, McKeown R. ADHD and health services utilization in the national health interview survey. J Atten Disord. 2009;12(4):330-340.
5. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
6. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1-10.
7. Dulcan M; AACAP Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S-121S.
8. Hurtig T, Ebeling H, Taanila A, et al. ADHD and comorbid disorders in relation to family environment and symptom severity. Eur Child Adolesc Psychiatry. 2007;16(6):362-369.
9. Rommelse NN, Altink ME, Fliers EA, et al. Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. J Abnorm Child Psychol. 2009;37(6):793-804.
10. McBurnett K, Pfiffner LJ. Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders. Postgrad Med. 2009;121(6):158-165.
11. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
12. Taylor AA, Pool JL. Clinical pharmacology of antihypertensive therapy. Semin Nephrol. 2005;25(4):215-226.
13. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086.
14. Pappadopulos E, Macintyre Ii JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003;42(2):145-161.
15. Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009;19(5):575-582.
16. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-120.
17. De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiatry. 2006;21(1):21-28.
18. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-347.
19. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):9-14.
20. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886-894.
21. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39(1):15-25.
22. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms. CNS Drugs. 2010;24(9):755-768.
23. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1551-1559.
24. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7-8):579-589.
25. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1996;53(5):448-455.
26. Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1285-1292.
27. Arnsten AF, Scahill L, Findling RL. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder:emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17(4):393-406.
28. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002;22(16):7264-7271.
29. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57(7-8):608-618.
30. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 suppl 2):S46-S53.
31. Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(1):12-13.
32. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3(5):386-396.
33. Volkow ND, Wang G-J, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.
34. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1(1):2.
35. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs. 2009;23(suppl 1):33-41.
36. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):376-384.
37. Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975;92(2):291-306.
38. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403-450.
39. Arnsten AFT, Cai JX. Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging. 1993;14(6):597-603.
40. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397-410.
41. Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17(suppl 1):i6-i15.
42. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. α2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13(6):770-776.
43. Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol. 1994;62(2):134-139.
44. Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport. 2003;14(7):1013-1016.
45. Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol Psychiatry. 2005;57(2):192-195.
46. 2-Adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int. 2009;55(7):447-453.
47. 35S]GTPγS binding. Biochem Pharmacol. 1998;55(7):1035-1043.
48. Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct. 2008;4:12.
49. 2C-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis. 2006;23(3):679-688.
50. Cho SC, Kim JW, Kim BN, et al. Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample. Neurosci Lett. 2008;446(2-3):108-111.
51. Uhlén S, Wikberg JE. Delineation of rat kidney alpha 2A-and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991;202(2):235-243.
52. Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol. 1980;10(suppl 1):71S-80S.
53. Biederman J, Melmed RD, Patel A, et al; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84.
54. Jain R, Kollins S, Bailey C, Holloway W, Horacek HJ, Khayrallah M. Developing a sustained release formulation of clonidine for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Poster presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, 2008; Scottsdale, AZ.
55. Hunt RD. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol Bull. 1987;23(1):111-114.
56. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry. 1985;24(5):617-629.
57. Hunt RD, Minderaa RB, Cohen DJ. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull. 1986;22(1):229-236.
58. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(1):50-54.
59. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-228.
60. Keränen A, Nykänen S, Taskinen J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol. 1978;13(2):97-101.
61. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47(2):189-198.
62. Fujimura A, Ebihara A, Ohashi K, et al. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol. 1994;34(3):260-265.
63. Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7(9):558-562.
64. Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29(4):617-625.
65. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253-1262.
66. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J; SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-165.
67. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047-1055.
68. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy [letter]. J Child Adolesc Psychopharmacol. 1995;5(4):301-304.
69. Kollins S, Findling RL, Wigal SB, Brams M, Segal SD, Khayrallah M. Modified-release clonidine for the treatment of children/adolescents with ADHD. Poster presented at: 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 27-November 1, 2009; Honolulu, HI.
70. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501-510.
71. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215-226.
72. Schatzberg AF. New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. CNS Spectr. 2006;11(12 suppl 15):22-27.